Skip to main content

Table 5 Correlates of uveitis inactivity on—or off medication for ≥ 6 months

From: Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study

 

Uveitis inactivity

on medication ≥ 6 months

Uveitis inactivity

off medication ≥ 6 months

 

OR

p value

95%CI

OR

p value

95%CI

Male sex

1.42

0.201

0.83; 2.44

1.23

0.723

0.39; 3.95

HLA-B27 positivity

0.55

0.216

0.21; 1.42

-

-

-

ANA positivity

1.01

0.978

0.53; 1.91

1.13

0.869

0.26; 5.02

Oligoarthritis, extended

1.56

0.504

0.42; 5.76

-

-

-

Oligoarthritis, persistent

2.61

0.103

0.82; 8.26

-

-

-

Psoriatic arthritis

3.04

0.261

0.44; 21.15

-

-

-

Enthesitis-related arthritis

0.48

0.464

0.07; 3.39

-

-

-

RF-negative polyarthritis

0.10

0.466

0.00; 45.33

-

-

-

Age at JIA onset

1.10

0.072

0.99; 1.22

1.17

0.083

0.98; 1.40

Age at uveitis onset

1.10

0.059

1.00; 1.21

1.09

0.386

0.90; 1.31

Duration JIA onset / uveitis onset [months]

1.00

0.776

0.99; 1.02

0.98

0.193

0.94; 1.01

Duration JIA onset / first DMARD [months]

1.01

0.171

0.99; 1.03

1.03

0.177

0.99; 1.07

Duration uveitis onset / first DMARD [months]

1.00

0.725

0.99; 1.01

0.96

0.029

0.93; 1.00

Duration uveitis onset / first bDMARD [months]

1.00

0.977

0.99; 1.01

1.00

0.601

0.98; 1.04

ESR at study enrollment

1.00

0.998

0.99; 1.01

0.98

0.287

0.95; 1.02

S100A12 at study enrollment

1.00

0.935

1.00; 1.00

1.00

0.228

1.00; 1.00

Any uveitis complication at initial uveitis visit

1.00

0.991

0.58; 1.72

0.37

0.239

0.07; 1.93

AC cella grade at initial uveitis visit

0.98

0.809

0.80; 1.19

0.77

0.284

0.47; 1.24

BCVA [LogMAR] at initial uveitis visit

1.22

0.622

0.55; 2.71

0.1

0.119

0.01; 2.74

cJADAS-10

0.78

< 0.001

0.73; 0.83

0.86

0.022

0.76; 0.98

Physicians global assessment

0.65

< 0.001

0.57; 0.74

0.68

0.014

0.50; 0.93

Number of joints with arthritis

0.60

< 0.001

0.48; 0.75

0.75

0.173

0.49; 1.14

Patient's global

0.68

< 0.001

0.61; 0.77

0.81

0.057

0.65; 1.01

C-HAQ

0.38

< 0.001

0.23; 0.64

0.16

0.056

0.02; 1.05

PedsQL, total

1.04

< 0.001

1.02; 1.06

1.02

0.134

0.99; 1.05

PedsQL, physical

1.03

< 0.001

1.02; 1.04

1.04

0.030

1.00; 1.07

PedsQL, psychosocial

1.03

< 0.001

1.01; 1.04

1.01

0.433

0.98; 1.04

ESR

0.96

< 0.001

0.94; 0.98

0.84

0.025

0.73; 0.98

CRP

0.95

0.026

0.90; 0.99

0.98

0.699

0.86; 1.11

S100A12

1.00

0.119

0.99; 1.00

0.99

0.186

0.98; 1.00

  1. ANA Antinuclear antibodies, RF Rheumatoid factor, JIA Juvenile idiopathic arthritis, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, AC Anterior chamber, BCVA Best-corrected visual acuity, LogMAR Logarithm of the minimum angle of resolution, cJADAS-10 Clinical Juvenile Arthritis Disease Activity Score, C-HAQ Childhood Health Assessment Questionnaire, PedsQL Pediatric Quality of Life, OR Odds ratio, CI Confidential interval; a in accordance with SUN classification (Jabs et al. 2005)
  2. inactive uveitis for at least 6 months; inactive uveitis for at least 6 months without topical corticosteroids or systemic anti-inflammatory medication (corticosteroids or DMARDs). Scores for arthritis activity and quality of life as well as ESR, CRP and S100A12 were assessed as mean over time
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us